Related Experiment Videos
Improved management of congestive heart failure. Use of continuous ambulatory peritoneal dialysis
Insights
Continuous ambulatory peritoneal dialysis (CAPD) offers significant symptom relief and improved well-being for patients with end-stage congestive heart failure (CHF). This treatment can be an effective option for those unresponsive to traditional therapies.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- End-stage congestive heart failure (CHF) poses significant challenges for patients unresponsive to conventional treatments.
- Heart transplantation is a viable option for some, but contraindications limit its applicability.
Observation:
- Four patients with advanced CHF, refractory to medical management, underwent continuous ambulatory peritoneal dialysis (CAPD).
- Treatment duration ranged from one to 21 months, demonstrating feasibility and tolerability.
Findings:
- All patients experienced a marked improvement in CHF symptoms, progressing from New York Heart Association Class IV to Class II.
- A significant enhancement in the patients' overall sense of well-being was observed.
- Three patients with contraindications for heart transplantation achieved professional rehabilitation.
Implications:
- CAPD emerges as a promising therapeutic strategy for managing end-stage CHF when standard treatments fail.
- This approach can improve quality of life and functional capacity in severe heart failure patients.
- CAPD may serve as a bridge to heart transplantation or as a long-term management solution.
Abstract:
Four patients suffering from end-stage congestive heart failure (CHF) refractory to conventional medical treatment were treated with continuous ambulatory peritoneal dialysis (CAPD) for one to 21 months. All four patients improved from class IV CHF to class II, as defined by the New York Heart Association, and experienced a definite improvement in their sense of well-being. Three patients, women between 42 and 59 years of age with contraindications for heart transplantation, were all professionally rehabilitated. One 21-year-old patient received CAPD until he underwent a successful orthotopic heart transplantation. We thus propose CAPD as an effective treatment for end-stage CHF refractory to conventional medical treatment.